-
公开(公告)号:US20210346384A1
公开(公告)日:2021-11-11
申请号:US17277475
申请日:2019-09-16
Applicant: PFIZER INC.
Inventor: Flavia Mercer PERNASETTI
IPC: A61K31/519 , A61K31/565 , A61P35/00 , A61K31/455
Abstract: This invention relates to a method of treating breast cancer by administering a TGFβ inhibitor in combination with a CDK inhibitor to a patient in need therof.
-
公开(公告)号:US20180002428A1
公开(公告)日:2018-01-04
申请号:US15610417
申请日:2017-05-31
Applicant: PFIZER INC.
Inventor: Shu-Hui LIU , Flavia Mercer PERNASETTI , Weihsien HO
IPC: C07K16/28 , A61K49/00 , A61K47/68 , A61K39/395 , A61K39/00 , C07K14/715
CPC classification number: C07K16/2866 , A61K39/3955 , A61K47/6803 , A61K47/6809 , A61K47/6847 , A61K47/6849 , A61K47/6851 , A61K49/0002 , A61K2039/505 , C07H21/04 , C07K14/7158 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N15/09
Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
-
公开(公告)号:US20150037328A1
公开(公告)日:2015-02-05
申请号:US14449478
申请日:2014-08-01
Applicant: Pfizer Inc.
Inventor: Shu-Hui LIU , Flavia Mercer PERNASETTI , Wei-Hsien HO
CPC classification number: C07K16/2866 , A61K39/3955 , A61K47/6803 , A61K47/6809 , A61K47/6847 , A61K47/6849 , A61K47/6851 , A61K49/0002 , A61K2039/505 , C07H21/04 , C07K14/7158 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N15/09
Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
Abstract translation: 本发明提供结合趋化因子受体4(CXCR4)的抗体和相关分子。 本发明进一步提供包含此类抗体的抗体 - 药物偶联物,编码抗体的核酸,以及获得此类抗体的方法。 本发明还涉及使用这些抗体和抗CXCR4抗体 - 药物偶联物治疗与CXCR4功能或表达相关的疾病(例如癌症)如结肠,RCC,食管癌,胃癌,头部和/ 颈,肺,卵巢,胰腺癌或血液癌。
-
-